ATYR (aTyr Pharma) Buildings And Improvements: $ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATYR aTyr Pharma Inc ATYR
20 GF Score
Price $0.38
GF Value $0.52
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is aTyr Pharma Buildings And Improvements?

aTyr Pharma ATYR +4.27% 20 Buildings And Improvements is $ Mil as of Jun. 2026. GuruFocus rates ATYR with a GF Score™ of 20/100 and a GF Value™ of $0.52 (Modestly Undervalued). The stock has 3 warning signs investors should review.

aTyr Pharma Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for aTyr Pharma's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

aTyr Pharma Buildings And Improvements Chart

aTyr Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buildings And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

aTyr Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
ATYR
20GF Score
aTyr Pharma Inc ATYR
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

aTyr Pharma Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of $ Mil mean?
aTyr Pharma (ATYR) has a Buildings And Improvements of $ Mil as of Jun. 2026. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on aTyr Pharma and its competitors.
Is aTyr Pharma's Buildings And Improvements too high?
aTyr Pharma's current Buildings And Improvements is $ Mil. Overall, aTyr Pharma has a GF Score™ of 20/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's Buildings And Improvements compare to TIL and AURX?
aTyr Pharma's Buildings And Improvements of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Biotechnology company?
A good Buildings And Improvements depends on the Biotechnology industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on aTyr Pharma and its competitors. aTyr Pharma's current Buildings And Improvements is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.52, compared to a current price of $0.38 — trading 27.2% below its estimated fair value. The current Buildings And Improvements is $ Mil. aTyr Pharma's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current Buildings And Improvements is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is aTyr Pharma (ATYR) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be undervalued. The current stock price of $0.38 is trading 27.2% below its estimated GF Value™ of $0.52. GuruFocus considers aTyr Pharma to be Modestly Undervalued.

Key valuation signals for ATYR:

  • Buildings And Improvements: $ Mil
  • GF Value™: $0.52 vs. price of $0.38 (27.2% below fair value)
  • GF Score™: 20/100 with 3 warning signs

No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

aTyr Pharma Business Description

Other Exchanges 471A:Germany
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
20GF Score

Get the complete analysis for ATYR

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price
$0.52
GF Value